A phase II/III Study of Paclitaxel/Carboplatin alone or Combined with either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-zzfx (PHESGO) in HER2 Positive Stage I-IV Endometrial Serous Carcinoma or C

Brief description of study

This study is a medical research project that aims to test different treatment options for newly diagnosed patients with HER2-positive endometrial serous carcinoma or carcinosarcoma. The study will involve three groups of patients. The first group will receive the usual treatment, which involves taking Paclitaxel and Carboplatin every three weeks for six cycles. The second group will receive Paclitaxel, Carboplatin, Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) along with HERCEPTIN HYLECTA maintenance therapy, which will be given every three weeks for six cycles and for up to a year after that. The third group will receive Paclitaxel/Carboplatin/Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO), following the same schedule as the second group. The patients will be assigned to these groups randomly and will be divided based on their stage of cancer, the type of cancer cells they have, and whether they will receive an additional type of therapy called vaginal brachytherapy. The researchers will closely monitor the safety and side effects of the treatment for the third group. They will also analyze the results during the study to decide if any of the groups should be discontinued and the study should move to a new phase. The main goals of the study are to measure how long the patients survive overall and without the cancer progressing. They will also look at other factors such as how well the treatment works, how long it lasts, and how safe it is. The study will follow ethical rules and regulations, and all patients will be asked for their permission before joining.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.